– USA, CA – Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of Shawn Tomasello to its Board of Directors.
“We are very excited to have Shawn join our Board as she brings an extensive track record in developing and commercializing pharmaceutical products,” said Martin Babler, CEO at Principia Biopharma. “With her broad sales and marketing expertise from several pioneering biotechnology and pharmaceutical companies and her experience in launching new products, Shawn is ideally suited to be part of Principia’s long-term vision.”
About Shawn Tomasello
With more than 30 years of experience in the pharmaceutical and biotech industries, Ms. Tomasello has substantial commercial and strategic experience. From 2015 to 2018, Ms. Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences. Prior to this, she served as chief commercial officer and oversaw the launch of Imbruvica at Pharmacyclics, Inc., which was subsequently acquired by AbbVie, Inc.
Ms. Tomasello previously was president of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. She received an MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati.
About Principia Biopharma
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency platform enables the company to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease. PRN2246/SAR442168, a covalent BTK inhibitor which crosses the blood-brain barrier, is being evaluated in Phase 2 clinical trial in patients with multiple sclerosis and has been partnered with Sanofi for that disease and other diseases of the central nervous system. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor is being evaluated in a Phase 1 trial in patients with bladder cancer.
For more information: https://www.principiabio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
